HIGHLIGHTS
- who: Eva Gonzu00e1lez Barca from the Hematology Department, Catalan Institute of Oncology, University of Barcelona, IDIBELL, Barcelona, Spain have published the article: Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era, in the Journal: (JOURNAL)
- what: This review describes updated data on the toxicity and efficacy of the IgG-like BsAbs that are currently being studied in lymphomas, especially in DLBCL. The aims were to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose.
SUMMARY
Diffuse large B-cell lymphoma (DLBCL . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.